VBI Vaccines, Inc. (VBIV)

NASDAQ: VBIV · IEX Real-Time Price · USD
0.706
-0.023 (-3.20%)
At close: Sep 30, 2022 4:00 PM
0.705
-0.001 (-0.11%)
After-hours: Sep 30, 2022 7:30 PM EDT
-3.20%
Market Cap 182.28M
Revenue (ttm) 660,000
Net Income (ttm) -101.58M
Shares Out 258.26M
EPS (ttm) -0.29
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 394,246
Open 0.700
Previous Close 0.729
Day's Range 0.700 - 0.740
52-Week Range 0.640 - 3.420
Beta 1.84
Analysts Buy
Price Target 6.12 (+767.1%)
Earnings Date Nov 7, 2022

About VBIV

VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the presentation of viruses to elicit a human immune system. Its lead eVLP progr... [Read more...]

Industry Biotechnology
Employees 149
Stock Exchange NASDAQ
Ticker Symbol VBIV
Full Company Profile

Financial Performance

In 2021, VBI Vaccines's revenue was $631,000, a decrease of -40.53% compared to the previous year's $1.06 million. Losses were -$69.75 million, 50.9% more than in 2020.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for VBIV stock is "Buy." The 12-month stock price forecast is 6.12, which is an increase of 767.10% from the latest price.

Price Target
$6.12
(767.10% upside)
Analyst Consensus: Buy
Stock Forecasts

News

VBI Vaccines Announces Initiation of Phase 1 Study of Multivalent Coronavirus Vaccine Candidate, VBI-2901

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announce...

3 days ago - Business Wire

VBI Vaccines Announces Presentation of Physician-Initiated Compassionate Use Data of its 3-Antigen Hepatitis B Vaccin...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announce...

1 week ago - Business Wire

VBI Vaccines Secures $100 Million Debt Facility From K2 HealthVentures

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announce...

2 weeks ago - Business Wire

Valneva and VBI Vaccines Announce European Partnership for Marketing and Distribution of PreHevbri®

SAINT-HERBLAIN, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (Valneva) and VBI Vaccines Inc. (Nasdaq: VBIV) (VBI) today announced a partnership in select Eu...

Other symbols: VALN
3 weeks ago - Business Wire

VBI Vaccines, Inc. (VBIV) Reports Q2 Loss, Misses Revenue Estimates

VBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of -157.14% and 50.78%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

VBI Vaccines Reports Second Quarter 2022 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announce...

1 month ago - Business Wire

Why Ocugen, Sorrento Therapeutics, and VBI Vaccines Are on the Move Today

Healthcare has become a bona fide stock picker's market this year.

Other symbols: OCGNSRNE
2 months ago - The Motley Fool

VBI Vaccines Announces Appointment of John Dillman as Chief Commercial Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announce...

2 months ago - Business Wire

VBI Vaccines Announces New Long-Term Follow-Up Clinical Data for its 3-Antigen Adult Hepatitis B Vaccine Presented at...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announce...

3 months ago - Business Wire

VBI Vaccines Announces Results of Annual General Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI" or the "Company"), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of dise...

3 months ago - Business Wire

VBI Vaccines Receives U.S. FDA Orphan Drug Designation for VBI-1901 for the Treatment of Glioblastoma

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announce...

3 months ago - Business Wire

VBI Vaccines to Participate in the Jefferies Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announce...

3 months ago - Business Wire

VBI Vaccines Presents Updated Phase 2a Tumor Response and Overall Survival Data for VBI-1901 in Recurrent GBM at the ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announce...

3 months ago - Business Wire

VBI Vaccines Announces UK MHRA Marketing Authorisation for PreHevbri™, a 3-Antigen Adult Hepatitis B Vaccine

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announce...

4 months ago - Business Wire

VBI Vaccines Announces Abstract Accepted for Oral Presentation at EASL 2022

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announce...

4 months ago - Business Wire

VBI Vaccines Presented Health Economics and Outcomes Research for PreHevbrio™ at the International Society for Pharma...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announce...

4 months ago - Business Wire

VBI Vaccines, Inc. (VBIV) Reports Q1 Loss, Lags Revenue Estimates

VBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of 0% and 3.08%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

VBI Vaccines Reports First Quarter 2022 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announce...

4 months ago - Business Wire

VBI Vaccines Announces European Commission Marketing Authorisation for PreHevbri™, a 3-Antigen Adult Hepatitis B Vaccine

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announce...

5 months ago - Business Wire

VBI Vaccines Announces Data from VBI-1901 in Recurrent Glioblastoma Patients Selected for Poster Discussion at the 20...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announce...

5 months ago - Business Wire

VBI Vaccines Announces New Data and Progress of VBI-2900, VBI's eVLP Coronavirus Program

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announce...

5 months ago - Business Wire

VBI Vaccines Announces PreHevbrio™ is Now Available in the United States for the Prevention of Hepatitis B in Adults

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, toda...

6 months ago - Business Wire

VBI Vaccines to Participate in the 32nd Annual Oppenheimer Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, toda...

6 months ago - Business Wire

VBI Vaccines, Inc. (VBIV) Reports Q4 Loss, Lags Revenue Estimates

VBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of 0% and 40.88%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

VBI Vaccines Reports Fourth Quarter and Full Year Financial Results for 2021, Provides Corporate Update and Outlook f...

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, toda...

6 months ago - Business Wire